Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.
about
Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.A pilot study of bortezomib in Korean patients with relapsed or refractory myelomaBortezomib plus thalidomide for newly diagnosed multiple myeloma in China.Thalidomide: dual benefits in palliative medicine and oncology.Immunotherapeutic and antitumour potential of thalidomide analogues.Thalidomide as an anti-cancer agent.Thalidomide for the treatment of relapsed and refractory multiple myeloma.Thalidomide in multiple myeloma--from the clinic to the laboratory.Thalidomide dosing in patients with relapsed or refractory multiple myeloma.Advances in the treatment of multiple myeloma: the role of thalidomide.Thalidomide: a new anticancer drug?Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.Thalidomide and its derivatives: new promise for multiple myeloma.Stem cell transplantation for multiple myeloma.Thalidomide for the treatment of multiple myeloma.Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center.Targeted therapy in multiple myeloma.Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.Drug insight: thalidomide as a treatment for multiple myeloma.A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.Lenalidomide in multiple myeloma.An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myelomaPhase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.Targeted treatments to improve stem cell outcome: old and new drugs.Current trends in multiple myeloma management.Thalidomide: an old drug with new action.Management of myeloma-associated renal dysfunction in the era of novel therapies.Antineoplastic drug-induced bradyarrhythmias.Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Glutamic acid and its derivatives: candidates for rational design of anticancer drugs.Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.Diagnosis and management of multiple myeloma.Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia.
P2860
Q33343492-279011FF-A47C-4D72-A3E1-B971E43FEC75Q33343690-4ECC053F-3F6D-43F4-B28B-4CFE65E0B4B0Q33364235-BF45B66D-F48A-4445-B518-A2892B25F1ADQ33367833-514D7B13-F40F-48F5-A870-32FDDDEB0718Q33391566-20B633E9-AD51-47EC-806B-C7FCD443B9BDQ34375023-CA8D37F7-C0BC-4794-8A50-743092CFDE73Q34451909-8EABF538-4D9A-440E-80D9-3FB83CACFF97Q34778074-3A12A980-0E65-4A15-8D37-594CBCA6C9BFQ34782279-F6E65533-C9AD-4D81-940A-931B49D7E12FQ35008319-96BBFFB3-D85A-4365-8577-672C4F79139AQ35092960-6C1033E4-8F4A-4FAC-A36D-FC66CDEA1708Q35104386-C6C13C0E-9D70-45F5-AE66-17BBFDF39E79Q35164773-1BA723CD-3A0F-445D-9990-28D9558FEC19Q35175287-A96514B3-A6EC-4A6C-ACC4-B6E7E409E4BDQ35198927-31B0DC1B-A07F-433A-8501-594B94895DFAQ35569462-C6B10E7A-0659-4C2D-870E-865D3DE3B1CEQ35692626-3D3F1F99-0767-44E1-9A6D-927A639F86BDQ35870500-B1E7D25F-1C45-45AF-BE0F-0DABA8BDD806Q35937159-B7F8F5D0-F6DB-44CC-9D2B-7A1E484BE129Q36108614-57B422F4-C2F3-478E-842B-CBB6AAD6E2C5Q36271114-4FEF8EB3-A6BA-4DC8-91BD-ECE62C705C5EQ36304004-F5E660B2-E3D4-48C8-98C0-B1E71C6451BAQ36381565-9CAF5481-A0C1-423E-AD3A-AA25BD92D3DBQ36573818-294065AB-4273-4B7B-90B4-2DC6C88EC913Q36695180-0A5E3507-29A9-4E55-B0DB-86079E19038BQ36696902-A6C90D43-1F03-49DF-BCE7-9AC7D51D6F86Q36927960-E4BB4AB4-3344-4425-AC2A-A798406493F0Q37183557-5B1C3A02-3C08-4602-85D2-8D8AB362F9EFQ37974744-1E3DDBC5-CA43-41BC-AFBB-1587CA3B6827Q37978343-ABAEA8E9-DFEC-46D3-BB03-D9D2D829A348Q38025714-2BA9AF6E-FB89-40C4-BCE1-832DA2AC9D3CQ38042444-002927F9-1B77-4CA4-A718-99E4468D012EQ38672091-09204EEF-8D4A-4863-929B-A846B8DE18C4Q39417367-3D89E9CA-63FB-4328-B076-DE78B931A290Q40672192-44D7828F-A754-483E-8A2F-A9E1272701A0Q43622707-3BF3DA24-7E9E-4E04-ACB9-17D2F73F4DE0Q43791388-E1EC918C-E0BC-466E-AA59-B40A1CB96960Q43817786-1979C125-15B5-49FC-9824-C46625C0E0F7Q43973073-8D61C2FF-837C-438C-8B33-3ADE14283B36Q43985644-C70D8C8E-FB8C-4CB4-A64C-41B1EAA9D59A
P2860
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Frequent good partial remissio ...... fractory and relapsed myeloma.
@en
Frequent good partial remissio ...... fractory and relapsed myeloma.
@nl
type
label
Frequent good partial remissio ...... fractory and relapsed myeloma.
@en
Frequent good partial remissio ...... fractory and relapsed myeloma.
@nl
prefLabel
Frequent good partial remissio ...... fractory and relapsed myeloma.
@en
Frequent good partial remissio ...... fractory and relapsed myeloma.
@nl
P2093
P2860
P1476
Frequent good partial remissio ...... fractory and relapsed myeloma.
@en
P2093
P2860
P356
10.1046/J.1365-2141.2000.01983.X
P407
P577
2000-04-01T00:00:00Z